REPROCELL and Histocell Achieve GMP Certification for Manufacturing Process of Clinical-Grade iPSC Master and Working Cell Banks Using StemRNA™ Clinical iPSCs
20 October 2025
REPROCELL and Histocell achieve GMP certification for clinical-grade iPSC manufacturing, advancing regenerative medicine and cell therapy production under EU regulations.
REPROCELL Announces U.S. FDA Drug Master File Submittal for StemRNA™ Clinical iPSC Seed Clones
22 July 2025
REPROCELL is pleased to announce the successful submittal of its StemRNA™ Clinical iPSC Seed Clones with the U.S. Food and Drug Administration (FDA) via a Type II Drug Master File (DMF).